GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (FRA:D4S) » Definitions » EV-to-EBITDA

Daiichinkyo Co (FRA:D4S) EV-to-EBITDA : 24.88 (As of Apr. 26, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Daiichinkyo Co's enterprise value is €48,252 Mil. Daiichinkyo Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €1,940 Mil. Therefore, Daiichinkyo Co's EV-to-EBITDA for today is 24.88.

The historical rank and industry rank for Daiichinkyo Co's EV-to-EBITDA or its related term are showing as below:

FRA:D4S' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.82   Med: 17.34   Max: 60.29
Current: 28.13

During the past 13 years, the highest EV-to-EBITDA of Daiichinkyo Co was 60.29. The lowest was 5.82. And the median was 17.34.

FRA:D4S's EV-to-EBITDA is ranked worse than
81.33% of 707 companies
in the Drug Manufacturers industry
Industry Median: 14.03 vs FRA:D4S: 28.13

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Daiichinkyo Co's stock price is €29.27. Daiichinkyo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.666. Therefore, Daiichinkyo Co's PE Ratio for today is 43.95.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Daiichinkyo Co EV-to-EBITDA Historical Data

The historical data trend for Daiichinkyo Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co EV-to-EBITDA Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.59 41.25 32.41 42.16 27.02

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.16 36.67 34.42 22.45 -

Competitive Comparison of Daiichinkyo Co's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's EV-to-EBITDA falls into.



Daiichinkyo Co EV-to-EBITDA Calculation

Daiichinkyo Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=48251.915/1939.543
=24.88

Daiichinkyo Co's current Enterprise Value is €48,252 Mil.
Daiichinkyo Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,940 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (FRA:D4S) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Daiichinkyo Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=29.27/0.666
=43.95

Daiichinkyo Co's share price for today is €29.27.
Daiichinkyo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.666.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Daiichinkyo Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (FRA:D4S) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (FRA:D4S) Headlines

No Headlines